Copyright © 2002 by the European Society of Cardiology.
Editorials
Early invasive strategy for acute coronary syndromes without persistent ST-segment elevation: Has the time come for ‘drive-through’ angiography?
a Duke University Medical Center, Durham, NC, U.S.A.
b University of North Carolina, Chapel Hill, NC, U.S.A.
References
- Simoons ML, Harrington RA. Optimizing treatment of acute coronary syndromes with GPIIb/IIIa inhibitors— Proceedings of the satellite symposium to the XXIst Congress of the European Society of Cardiology, Barcelona, Spain, August 1999—Foreword. Eur Heart J Suppl. 2000;2:C1
- Braunwald E, McCabe CH, Cannon CP. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-q-wave myocardial infarction—results of the TIMI IIIB Trial. Circulation. 1994;89:1545–1556
[Abstract/Free Full Text] - Boden WE, O'Rourke RA, Crawford MH. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. N Engl J Med. 1998;338:1785–1792
[Abstract/Free Full Text] - Wallentin L, Swahn E, Kontny F. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet. 1999;354:708–715[CrossRef][Web of Science][Medline]
- Cannon CP, Weintraub WS, Demopoulos LA. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 2001;344:1879–1887
[Abstract/Free Full Text] - Spacek R, Widimsky P, Straka Z. Value of first day angiography/angioplasty in evolving non-ST segment elevation myocardial infarction. An open multicenter randomized trial. VINO study. Eur Heart J. 2002;23:230–238
[Abstract/Free Full Text] - Eur Heart J. 21;:1406–1432
- Braunwald E, Antman EM, Beasley JW. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American college of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol. 2001;38:294–295
[Free Full Text] - Califf RM, Abdelmeguid AE, Kuntz RE. Myonecrosis after revascularization procedures. J Am Coll Cardiol. 1998;31:241–251
[Abstract/Free Full Text] - Mahaffey, KW, Roe, MT, Dyke, CK, PARAGON B Investigators, Misreporting of myocardial infarction end points: Results of adjudication by a central clinical events committee in the PARAGON-B trial, Am Heart J
- Newby LK, Ohman EM, Christenson RH. Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin T-positive status—The PARAGON-B troponin T substudy. Circulation. 2001;103:2891–2896
[Abstract/Free Full Text] - Kaul P, Fu YL, Chang WC. Prognostic value of ST segment depression in acute coronary syndromes: Insights from PARAGON-A applied to GUSTO-IIb. J Am Coll Cardiol. 2001;38:64–71
[Abstract/Free Full Text] - Greenbaum AB, Harrington RA, Hudson MP. Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes. J Am Coll Cardiol. 2001;37:492–498
[Abstract/Free Full Text]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. P. Cannon Small molecule glycoprotein IIb/IIIa receptor inhibitors as upstream therapy in acute coronary syndromes: Insights from the TACTICS TIMI-18 trial J. Am. Coll. Cardiol., February 19, 2003; 41(4_Suppl_S): 43S - 48S. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||